Cryoprecipitate production: The use of additives to enhance the yield

Clinical and Laboratory Haematology

Volumn 28, Issue 4, 2006, Pages 237-240

  Yousef, H ^a   Neurath, D ^a   Freedman, M ^a   Rock, G ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Additives; Cryoprecipitate

Indexed keywords

BLOOD CLOTTING FACTOR 8; CALCIUM; CALCIUM CHLORIDE; CITRATE SODIUM; CITRIC ACID; FIBRINOGEN; FRESH FROZEN PLASMA;

ARTICLE; CRYOPRECIPITATE; CRYOPRECIPITATION; HUMAN; PLASMA; PRIORITY JOURNAL;

CALCIUM CHLORIDE; CITRATES; FACTOR VIII; FIBRINOGEN; HUMANS; PLASMA;

EID: 33746347960     PISSN: 01419854     EISSN: 13652257     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2006.00785.x     Document Type: Article

References (17)

1. AABB (2002) AABB Technical Manual, 14th edn, p. 746. American Association of Blood Banks, Bethesda, Maryland, USA.
2. Auerswald G., Spranger T. & Brackmann H.H. (2003) The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 88, EREP05.
3. Cumming A.M., Wensley R.T. & Delamore I.W. (1986) The assay of factor VIII:C in heparinized plasma: a polybrene neutralization method. Thrombosis and Haemostasis 55, 58-60.
4. Farrugia A. & Giangrande P. (2004) Choice of replacement therapy for hemophilia - cryoprecipitate issues: a rebuttal. Journal of Thrombosis and Haemostasis 2, 1022-1023.
5. Farrugia A., Douglas S., James J., Whyte G. & Herrington R. (1990) Use of plasma with high levels of ionized calcium in the production of model scale coagulation factor concentrates. Thrombosis and Haemostasis 64, 374-378.
6. Gosh K. (2004) Management of hemophilia and its complication in developing countries. Journal of Clinical Haematology 26, 243-251.
7. Hoots W.K. (2001) The future of plasma-derived clotting factor concentrates. Haemophilia 7(Suppl. 1), 4-9.
8. Krachmalnicoff A. & Thomas D.P. (1983) The stability of factor VIII in heparinized plasma. Thrombosis and Haemostasis 49, 224-227.
9. Mason E.C. (1978) Thaw-siphon technique for production of cryoprecipitate concentrate of factor VIII. Lancet 2, 15-17.
10. Menitove J. (2004) 5.7.5.14 Standards of Blood Banks and Transfusion Services, 23rd edn, p. 30. American Association of Blood Banks, Bethesda, MD, USA.
11. Mikaelsson M.E., Forsman N. & Oswaldsson U.M. (1983) Human factor VIII: a calcium-linked protein complex. Blood 62, 1006-1015.
12. Morgenthaler J.J., Zuber T. & Friedli H. (1985) Influence of heparin and calcium chloride on assay, stability, and recovery of factor VIII. Vox Sanguinis 48, 8-17.
13. Rock G.A., Cruickshank W.H., Tackaberry E.S. & Palmer D.S. (1979) Improved yields of factor VIII from heparinized plasma. Vox Sanquinis 36, 294-300.
14. Rock G.A., Cruichshank W.H., Tackaberrt E.S., Ganz P.R. & Palmer D.S. (1983) Stability of VIII:C in plasma: the dependence on protease activity and calcium. Thrombosis Research 29, 521-535.
15. Rock G.A., Tittley P. & Fuller V. (1988) Effect of citrate anticoagulants on factor VIII levels in plasma. Transfusion 28, 248-252.
16. Shanbrom E. & Owens W.J. (2001) A novel method to enhance the formation of cryoprecipitate from fresh plasma. Blood 98, 60a.
17. Smit Sibinga C.T., Daenen S.M., van Imhoff G.W., Maas A. & Das P.C. (1984) Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate. Thrombosis and Haemostasis 51, 12-15.